On November 22, 2024, Fosun Pharma announced the implementation of the third equity incentive plan for its holding subsidiary Health Jiangkangfu. This plan involves granting a total of 2 million yuan of investment platform partnership shares to 3 current directors and senior executives of the company, accounting for 0.5333% of the total registered capital of Health Jiangkangfu. The grant has been approved by the Fosun Pharma board of directors and does not require shareholder approval. Health Jiangkangfu's equity incentive plan aims to improve the company's corporate governance structure, enhance the sense of responsibility and mission of the management team and core employees. Since the plan started on September 14, 2023, multiple follow-up investments and option grants have been completed, totaling 35 million yuan of investment...Show More

On November 22, 2024, Fosun Pharma announced the implementation of the third equity incentive plan for its holding subsidiary Health Jiangkangfu. This plan involves granting a total of 2 million yuan of investment platform partnership shares to 3 current directors and senior executives of the company, accounting for 0.5333% of the total registered capital of Health Jiangkangfu. The grant has been approved by the Fosun Pharma board of directors and does not require shareholder approval. Health Jiangkangfu's equity incentive plan aims to improve the company's corporate governance structure, enhance the sense of responsibility and mission of the management team and core employees. Since the plan started on September 14, 2023, multiple follow-up investments and option grants have been completed, totaling 35 million yuan of investment platform partnership shares and 20.67 million yuan of option platform partnership shares granted to multiple incentive recipients. The price of this grant is 1.0173 yuan/registered capital, consistent with the pricing principle of the previous grant. The 3 investment parties involved in this grant are Chen Qiyu, Chen Yuqing, and Hu Hang, all of whom are related parties of the company, thus constituting related-party transactions. During the review of the relevant proposals by the Fosun Pharma board of directors, the related directors abstained from voting, and the remaining directors unanimously approved. This grant does not constitute a major asset restructuring and has a positive impact on the overall interests of the company.